The Top Biggest & Valuable Pharma Companies in World

From Johnson & Johnson to GlaxoSmithKline, we take a look at the Top biggest pharma companies in the world right now, according to Brand Finance

Pharma companies

US drug giant Johnson & Johnson is said to be worth $10.9bn and remains by far the most valuable company — by brand — in the industry and the ramaining list for the most biggest pharmaceutical companies are listed below.

This despite an 11% drop in the firm’s brand value — defined by Brand Finance as the net economic benefit an owner would achieve by licensing the brand in the open market.

Other established firms, such as Bayer and Pfizer, have also experienced a sharp decline in terms of financial worth, and brand strength — the performance, reputation and public image of a company relative to its competitors — compared to 2019.

In its report, Brand Finance highlighted the economic growth of Swiss company Roche, and debuts in the top 25 for Asian firms Sinopharm and Takeda, based in China and Japan respectively.

We take a look at each of the eight highest-ranked pharmaceutical companies in the world right now, according to Brand Finance.

The 10 biggest pharma companies, according to Brand Finance

1. Johnson & Johnson

Founded in 1886, American pharma and medical devices corporation Johnson & Johnson maintained its place at the top of Brand Finance’s rankings for 2020 thanks to investment into antimicrobial research.

The company also recently became one of the first in the world to reveal it was working on a vaccine for the novel coronavirus.

Notable Johnson & Johnson consumer products include Band-Aid, Tylenol medications, and Johnson’s baby wipes and shampoos.

biggest pharma companies johnson & johnson
Johnson & Johnson is perhaps best known for its range of consumer baby products (Credit: Mike Mozart/Flickr)

In the Financial Times’ Global 500 rankings in 2019, Johnson & Johnson was also listed as one of the world’s most valuable companies, with 134,000 worldwide employees, 250 subsidiary businesses, and annual revenue of more than $80bn.

Its brand value is estimated at $10.9bn — the highest in the world — despite failing to reach its financial targets in the final quarter of 2019.

Johnson & Johnson’s brand strength is ranked as fourth behind Roche, Bayer and fellow US firm Bristol-Myers Squibb.

2. Roche

Some way behind Johnson & Johnson with a brand value of $7.6bn is Roche — a Basel-headquartered pharmaceutical and diagnostics firm. This signifies a 10% increase compared with last year.

Brand Finance puts this down to the company’s renewed commitment to cancer research and an expanding market in China.

The report also highlighted that Roche has continued to pull away from Novartis — its closest Swiss rival in the pharma industry.

The company is seen to have the best brand strength in its sector — climbing two places compared to 2019. It is the only pharma firm to boast an AAA- rating for brand strength this year as well.

Roche is active in more than 100 countries and employs about 94,000 people worldwide. Its annual revenue in 2018 was $57bn.

It is best known for its research and development of drugs for viruses and metabolic diseases, as well as cancer treatments.

3. Bayer

German pharma heavyweight Bayer maintained its place as the third biggest brand in the industry in spite of a 17% decrease in value compared to last year.

The company, which has famously sponsored German football team Bayer Leverkusen for more than 100 years, now has a brand value of $5.1bn.

Despite previously experiencing three years of growth, its acquisition of US crop science company Monsanto has finally taken its toll on the firm’s reputation and financial performance according to Brand Finance.

While the Monsanto deal has been recognised as “catastrophic” by its stakeholders, Bayer is now on the right track again following its acquisition of cell therapy company BlueRock Therapeutics.

Bayer’s most notable products are in the areas of human and veterinary drugs, consumer healthcare items, and agricultural and biotech products including genetically-engineered crops and pesticides.

4. Abbott

US medical devices and healthcare company Abbott Laboratories is valued at $4.5bn by Brand Finance — a 2.6% increase on last year.

It works across healthcare selling medical devices, diagnostic tools, branded medicines, and nutritional products and nutraceuticals.

Abbott was originally founded in 1888 as a drug development company —  but it split from its pharma research roots in 2013, forming separate spin-off firm AbbVie. AbbVie has been ranked as the 10th most valuable company in Brand Finance’s Pharma 25.

In 2018 Abbott generated more than $30bn in revenue, and the Illinois-based company has more than 100,000 employees worldwide.

5. Merck & Co

US pharmaceutical firm Merck & Co was originally founded as part of a German corporation going by the same name, and is therefore branded as Merck Sharp & Dohme (MSD) outside of the US and Canada.

Its brand value in 2020 is $4.3bn —  a 3.7% increase on last year.

Merck & Co currently sells more than 50 different prescription products in areas including cardiovascular and respiratory disease, oncology, neuroscience, vaccines, and even animal health.

At the start of the 21st century, Merck drew widespread criticism when one of its products —  an anti-inflammatory drug to relieve acute pain called Vioxx — was found to substantially increase the incidence of heart attacks and strokes among its users.

It was withdrawn from the market in 2004, and three years later the company announced a $4.85bn settlement with affected consumers in one of the biggest pharmaceutical lawsuits in history.

6. Pfizer

Pfizer’s brand value has dipped by more than 20% compared to last year, making it the fastest-falling brand on the Pharma 25.

Despite still being valued at $3.8bn, this fall saw it overtaken by US rivals Abbott and Merck in 2019.

Brand Finance has attributed this to an underwhelming joint venture with UK drug firm GlaxoSmithKline, and association with Mylan — an American pharmaceutical group that was involved in a 500% price hike of the EpiPen allergy medication as recently as 2017.

Despite this, Pfizer remains one of the biggest drug firms in the world having reported revenue of more than $53bn in 2018, and selling its products to more than 125 countries globally.

7. Sanofi

Fourth on the top 10 pharma list is French pharmaceutical company, Sanofi. The company saw 7.1%% revenue growth within its pharmaceutical sector, which contributes a substantial percentage of the company’s total revenue. Over 25% of this revenue came from Sanofi’s three best selling drugs, Lantus, an insulin injection for diabetes, Lovenox, an anticoagulant to prevent blood clots, and Aubagio, the one-daily pill to treat a form of multiple sclerosis. 

8. GlaxoSmithKline

gsk brands

The UK’s biggest pharma company GlaxoSmithKline (GSK) held its place above Novartis and BMS — in 12th — with a brand value of $3.5bn.

This is a 7% increase compared to last year — growth that has seen it jump above French company Sanofi, and Swiss multinational Novartis.

GSK predominantly develops prescription medicines, everyday consumer products and vaccines.

It is also a comparatively new pharma company having been founded in 2000. Despite this, the firm generated nearly $31bn in revenue in 2018 and currently has about 100,000 employees working in 150 different countries.

GSK recently announced it would be joining forces with the Coalition for Epidemic Preparedness Innovations to develop a vaccine for the novel coronavirus.


One of the leading pharmaceutical companies in Switzerland, Novartis comfortably makes the top 10 pharma list for 2019. The company focuses on a wide range of disease areas including oncology, immunology/dermatology, neuroscience and respiratory. The company’s revenue grew by 5.8% compared with 2017 figures despite a few top selling drugs facing generic competition in major markets, such as as oncology success Gleevec, and blood pressure drugs Diovan and Exforge. To combat these losses, Novartis spent 18% of their overall 2017 revenue on research & development in 2018. Currently, Novartis’ best selling drugs are Gilenya, for multiple sclerosis, and Lucentis, for patients suffering from eye-degenerative diseases.

10. Bristol-Myers Squibb (BMS) 

A new entry into the top 10 pharma list is Bristol-Myers Squibb, a leading American pharmaceutical company headquartered in New York City. BMS specialises in four key therapy areas: oncology, cardiovascular, immunoscience and fibrosis. The company’s strong growth in 2018 can be in part attributed to continued success of leading drugs Opdivo (cancer) and Eliquis (a blood thinner). BMS’ success is likely to be further boosted following the company’s planned acquisiton of Celgene – an innovative oncology biotech – in early 2019. This strategic acquisition will help position BMS as a leading biopharma player thanks to Celgene’s robust pipeline.

Leave a Reply

Your email address will not be published. Required fields are marked *